PT  - JOURNAL ARTICLE
AU  - Godwin Okeke Kalu
AU  - Joel M Francis
AU  - Latifat Ibisomi
AU  - Tobias Chirwa
AU  - Juliana Kagura
TI  - Factors associated with the uptake of Intermittent Preventive Treatment (IPTp-SP) for malaria in pregnancy: further analysis of the 2018 Nigeria Demographic and Health Survey
AID  - 10.1101/2022.06.23.22276819
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.23.22276819
4099  - http://medrxiv.org/content/early/2022/06/23/2022.06.23.22276819.short
4100  - http://medrxiv.org/content/early/2022/06/23/2022.06.23.22276819.full
AB  - Pregnancy-associated malaria is preventable and curable with intermittent preventive treatment with Sulfodoxine-Pyrimethamine (IPTp-SP). However, despite the effectiveness of IPTp-SP against malaria in pregnancy, the uptake among pregnant women in Nigeria remains very low. Thus, this study aimed to establish the factors associated with the uptake of at least one dose and optimal doses of IPTp-SP among pregnant women aged 15 to 49 years living in Nigeria in 2018. The study included 12,742 women aged 15 to 49 years with live births two years before or during the 2018 Nigeria Demographic Health Survey (NDHS) in the analysis. Descriptive analysis was carried out to determine the prevalence of IPTp-SP uptake. Multivariable logistic regression was used to establish the factors associated with receiving IPTp-SP during pregnancy, adjusting for possible confounding factors. Given the complex survey design, all analyses adjusted for sampling weight, stratification and clustering. The p-value of <0.05 was considered significant. In 2018, the prevalence of at least one dose of IPTp-SP was 63.6% (95% CI:62.0–65.1), and optimal doses of IPTp-SP were 16.8% (95% CI:15.8–17.8) during pregnancy. After the multivariable analysis, age group, region, frequency of ANC visits, belief in IPTp-SP effectiveness, and morbidity caused by malaria predicted the uptake of at least one IPTp-SP dose. Similar maternal characteristics, including household wealth index, spouse’s educational level and media exposure, were significantly associated with taking optimal IPTp-SP doses. For instance, women in the wealthiest households whose husbands had secondary education predicted a four-fold increase in uptake of at least one IPTp-SP dose (aOR:4.17; 95% CI:1.11–8.85).The low prevalence and regional variations of IPTp-SP uptake in the study area imply that most pregnant women in Nigeria are at substantial risk of pregnancy-associated malaria. Therefore, stakeholders should explore context-specific strategies to improve the IPTp-SP coverage across the regions in Nigeria.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTDR supported this research work as part of the Special Programme for Research and Training in Tropical Diseases (TDR). TDR is hosted by the World Health Organization and co-sponsored by UNICEF, UNDP, the World Bank and WHO. The TDR grant number: B40299. The funders did not play a role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Nigeria DHS 2018 was conducted by the Nigerian Population Commission in collaboration with the National Malaria Elimination Programme (NMEP) of the Federal Ministry of Health, Nigeria. Before each interview during the 2018 NDHS survey, all respondents provided informed consent, and the fieldworker ensured confidentiality. The respondents’ records were coded and de-identified (19). For this study, permission for NDHS 2018 dataset for secondary data analysis has been obtained from ICF International – Measure DHS website. Ethics approval was obtained from the University of the Witwatersrand Human Research Ethics Committee (Medical) – M2011103.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset for the study was obtained with permission from the Demographic and Health Surveys (DHS) Program. The dataset are publicly available and may be requested from the DHS Program office via https://www.dhsprogram.com/data/dataset_admin/. The questionnaire used for the analyses is the women’s questionnaire contained within the 2018 NDHS. https://www.dhsprogram.com/data/dataset_admin/ https://www.dhsprogram.com/publications/publication-fr359-dhs-final-reports.cfm